Malik Fady Ibraham

Malik Fady Ibraham, EVP of Research & Development, has demonstrated a consistent pattern of selling activity in Cytokinetics (CYTK) shares, with no recent purchases recorded. Over 34 reported transactions across two companies, Ibraham has sold approximately $2.42 million worth of stock compared to $265,000 in buys—a nearly 10:1 ratio favoring disposals. His most recent trades in March 2026 included two sizable CYTK sales totaling $747,850.95 on March 17, preceded by a $176,513.04 sale on March 9. The transactions form part of an extended divestment trend, with 11 sales since November 2025 averaging roughly $140,000 per transaction, including multiple six-figure disposals like a $146,190 sale on November 18, 2025, and a $136,667.25 transaction on November 4, 2025. The filings show Ibraham’s activity is concentrated exclusively in CYTK, with no trades in other companies since at least September 2025. Notably, several sales coincide with smaller "M"-coded acquisitions—likely option exercises—such as a $23,320 acquisition on December 16, 2025, preceding a $134,728 sale the same day. While three "A"-coded awards with $0 reported value appear in March 2026, these represent equity grants rather than market purchases. The absence of open-market buying and the recurring pattern of sales, particularly the two high-value March 2026 disposals, suggest a sustained reduction in Ibraham’s CYTK holdings over the past six months.